STOCK TITAN

PainReform Ltd - PRFX STOCK NEWS

Welcome to our dedicated news page for PainReform (Ticker: PRFX), a resource for investors and traders seeking the latest updates and insights on PainReform.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PainReform's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PainReform's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
40.87%
Tags
offering
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-51.58%
Tags
offering
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.19%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.17%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.61%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.65%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.2%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.99%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.3%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.69%
Tags
clinical trial
PainReform Ltd

Nasdaq:PRFX

PRFX Rankings

PRFX Stock Data

3.08M
1.12M
6.17%
29.93%
0.13%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Israel
Tel Aviv

About PRFX

painreform is a specialty pharmaceutical company that develops products for the treatment of pain. focused on reformulations of established pain drugs for the us fda 505(b)(2) regulatory pathway, painreform applies unique technologies to enhance efficacy, reduce adverse effects and increase convenience. our mission is to offer pain therapeutics with clinically meaningful benefits to both physicians and patients.